Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045136 · ClinicalTrials.gov registry record · Phase 1
Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
A Phase 1 study, sponsored by Poniard Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00045136 is a Phase 1 study that has completed, run by Poniard Pharmaceuticals.
The verdict
NCT00045136, a Phase 1 study, has completed, sponsored by Poniard Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Holmium Ho 166 DOTMP may deliver radiation directly to cancer cells and cause less damage to normal tissue. Combining chemotherapy and holmium Ho 166 DOTMP with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and holmium Ho 166 DOTMP and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining holmium Ho 166 DOTMP with melphalan and peripheral stem cell transplantation in treating patients who have multiple myeloma.
Interventions
- DRUG melphalan
- PROCEDURE peripheral blood stem cell transplantation
- RADIATION holmium Ho 166 DOTMP
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00045136
The ClinicalTrials.gov registry entry for NCT00045136 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Poniard Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which melphalan is the first listed.
NCT00045136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00045136 about?
NCT00045136 is a clinical study titled "Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Holmium Ho 166 DOTMP may deliver radiation directly to cancer cells and cause less damage to normal tissue. Combining chemotherapy and holmium Ho 166 DOTMP with peripheral stem ce...
What is the current status of trial NCT00045136?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-01.
What interventions are being tested in trial NCT00045136?
The interventions under investigation include: melphalan (DRUG), peripheral blood stem cell transplantation (PROCEDURE), holmium Ho 166 DOTMP (RADIATION).
Who is sponsoring clinical trial NCT00045136?
This trial is sponsored by Poniard Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.